A missense mutation accelerating the gating of the lysosomal Cl(-)/H(+)-exchanger ClC-7/Ostm1 causes osteopetrosis with gingival hamartomas in cattle by Sartelet, A. et al.
© 2014. Published by The Company of Biologists Ltd | Disease Models & Mechanisms (2014) 7, 119-128 doi:10.1242/dmm.012500
119
ABSTRACT
Chloride-proton exchange by the lysosomal anion transporter ClC-
7/Ostm1 is of pivotal importance for the physiology of lysosomes and
bone resorption. Mice lacking either ClC-7 or Ostm1 develop a
lysosomal storage disease and mutations in either protein have been
found to underlie osteopetrosis in mice and humans. Some human
disease-causing CLCN7 mutations accelerate the usually slow
voltage-dependent gating of ClC-7/Ostm1. However, it has remained
unclear whether the fastened kinetics is indeed causative for the
disease. Here we identified and characterized a new deleterious ClC-
7 mutation in Belgian Blue cattle with a severe symptomatology
including perinatal lethality and in most cases gingival hamartomas.
By autozygosity mapping and genome-wide sequencing we found a
handful of candidate variants, including a cluster of three private
SNPs causing the substitution of a conserved tyrosine in the CBS2
domain of ClC-7 by glutamine. The case for ClC-7 was strengthened
by subsequent examination of affected calves that revealed severe
osteopetrosis. The Y750Q mutation largely preserved the lysosomal
localization and assembly of ClC-7/Ostm1, but drastically accelerated
its activation by membrane depolarization. These data provide first
evidence that accelerated ClC-7/Ostm1 gating per se is deleterious,
highlighting a physiological importance of the slow voltage-activation
of ClC-7/Ostm1 in lysosomal function and bone resorption.
KEY WORDS: CLCN7, Hamartomas, Osteopetrosis, Lysosomal
storage, Ion homeostasis, Belgian Blue cattle
INTRODUCTION
Osteopetrosis, also known as marble bone disease, is a heterologous
group of inherited disorders that is characterized by fragile bones,
generally caused by an impaired bone resorption by osteoclasts
(Tolar et al., 2004). Children affected by severe osteopetrosis are
often blind due to compression of the optical nerve, and the patients
usually die within the first decade of life as a result of secondary
defects caused by bone marrow insufficiency. Two of the genes
whose mutations cause osteopetrosis are CLCN7 and OSTM1,
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encoding the chloride-proton (Cl–/H+) exchanger ClC-7 and its
obligate β-subunit Ostm1 (osteopetrosis-associated transmembrane
protein 1) (Chalhoub et al., 2003; Kornak et al., 2001; Lange et al.,
2006; Leisle et al., 2011). At least in mice, dysfunction of ClC-
7/Ostm1 additionally leads to a neuronal ceroid lipofuscinosis
(NCL)-like lysosomal pathology (Kasper et al., 2005; Lange et al.,
2006), and a severe form of osteopetrosis is accompanied by
neurodegeneration and accumulation of ceroid lipofuscin in humans
(Steward, 2003).
ClC-7 belongs to the CLC family of chloride channels and
transporters, which consists of nine mammalian members with
diverse physiological roles (Stauber et al., 2012). The CLC family
comprises both plasma membrane-localized chloride channels and
chloride–proton exchangers that reside predominantly on
compartments of the endocytic pathway (Jentsch, 2008; Stauber et
al., 2012). ClC-7 and its β-subunit Ostm1 localize to lysosomes of
all cells and additionally reside at the ruffled border membrane of
bone-resorbing osteoclasts (Kornak et al., 2001; Lange et al., 2006).
The latter specialized plasma membrane domain is built up by
lysosomal exocytosis and serves to acidify the resorption lacuna, a
process required for the degradation of bone material (Teitelbaum,
2000). Both the formation of the ruffled border and the acidification
of the resorption lacuna depend on functional ClC-7/Ostm1 (Kornak
et al., 2001; Lange et al., 2006). Hence, dysfunction of ClC-7/Ostm1
leads to osteopetrosis in mice and humans (Chalhoub et al., 2003;
Kornak et al., 2001; Lange et al., 2006). Contrasting with the impact
on the pH of the resorption lacuna, the lysosomal pH is not changed
in cells lacking either ClC-7 or Ostm1 (Kasper et al., 2005; Lange
et al., 2006; Steinberg et al., 2010; Weinert et al., 2010). In spite of
normal lysosomal pH, lysosomal degradation of endocytosed protein
is impaired in ClC-7/Ostm1-deficient mice (Wartosch et al., 2009),
which develop a neurodegenerative lysosomal storage disease in
addition to osteopetrosis (Kasper et al., 2005; Lange et al., 2006;
Pressey et al., 2010). Like the other intracellular CLCs, ClC-
7/Ostm1 mediates voltage-dependent Cl–/H+ exchange, but is unique
in its slow activation and deactivation in response to voltage steps
(Leisle et al., 2011). Intriguingly, several osteopetrosis-causing
human mutations accelerate this gating process (Leisle et al., 2011).
Many of these accelerating mutations change amino acids close to
the interface between cytosolic CBS domains and the
transmembrane part of ClC-7, suggesting that a physical interaction
between these parts is involved in ClC-7 gating (Leisle et al., 2011).
However, as we lacked data on the expression levels and subcellular
localization of the mutant proteins in affected tissues, it remains
unclear whether accelerated gating per se causes the human
pathology.
The Belgian Blue cattle breed (BBCB; Bos taurus) is a beef breed
from Belgium, famous for its hyper-muscled appearance caused by
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a spontaneous myostatin knockout allele (Grobet et al., 1997). The
BBCB population comprises approximately half a million cows and
2500 registered bulls. Extensive use of artificial insemination (about
half of births), associated with intense selection for traits related to
meat production, contracts the effective population size (Ne ~60),
thereby causing frequent outbursts of recessive defects.
In 2005, endorsed by breeders and veterinarians, we established
a heredo-surveillance platform to centralize relevant information and
biological samples for emerging genetic anomalies, identify
responsible genes and mutations, and develop diagnostic tests. Since
then, we have mapped and identified the causative gene and
mutation(s) for 12 and eight diseases, respectively, including
congenital muscular dystonia I and II, crooked tail syndrome and
stunted growth in BBCB (Charlier et al., 2008; Fasquelle et al.,
2009; Sartelet et al., 2012a; Sartelet et al., 2012b). These successes
were largely due to the development of medium-density single-
nucleotide polymorphism (SNP) chips (~50 K) for cattle, allowing
efficient autozygosity mapping in what equates to a small,
genetically isolated population. However, like in other domestic
animal species, the downside of the peculiar demography is the
limited mapping resolution that can be achieved. Depending on local
gene density, segments of autozygosity typically cover tens to a
hundred of positional candidate genes. In the absence of obvious
functional candidates, pinpointing the causative gene and mutation
remains slow and laborious.
In this study, by combining medium-density SNP arrays and
whole-genome sequencing (WGS) we identified a missense
mutation in CLCN7 as responsible for a symptomology in newborn
BBCB calves that encompasses abnormal skull formation and often
gingival hamartomas and stillbirth. Further analysis of affected
calves revealed a severe osteopetrosis and signs of lysosomal
storage. Although the mutation neither altered expression levels nor
the localization of ClC-7, it accelerated its gating kinetics. These
data strongly suggest a functional role of the slow gating kinetics of
ClC-7/Ostm1 for lysosomal function and bone resorption.
RESULTS
The gene for gingival hamartomas maps to a 1.3 Mb interval
on bovine chromosome 25
Between 2008 and 2010, we collected biological material with
pedigree records for 63 newborn calves with shared
symptomatology: affected calves were mostly stillborn (70%) or
slightly premature (gestation length between 210 and 260 days;
73%) and displayed a small body size (45%) and abdominal hydrops
(58%), an abnormal skull shape (100%), inferior brachygnatism
(100%), protruding tongue (81%) and gingival hamartomas of
variable size (up to 15 cm diameter; 80%) located on the lower jaw
(Fig. 1 and supplementary material Table S1). All calves born alive
were blind and consequently euthanized within days or weeks. At
necropsy, we observed liver (82%; Fig. 1) and kidney (59%; not
shown) hypertrophies. Mothers of affected calves typically suffered
from hydramnios, a condition commonly associated with impaired
swallowing in the fetus (Drost, 2007). As a result, ~50% of the dams
needed to be culled after parturition, causing considerable extra
losses to farmers. Examination of the pedigrees of the 63 cases
suggested a recessive mode of inheritance as all of them traced back
on both paternal and maternal side to a common ancestor (Gabin
d’Offoux, a sire born in 1977). Thirty-three cases and 275 healthy
controls were initially genotyped using a previously described
custom bovine 50K SNP array (Charlier et al., 2008). We performed
a genome-wide haplotype-based association study with a
generalized linear mixed model accounting for stratification using
GLASCOW (Zhang et al., 2012). We identified a single genome-
wide significant signal (P<10−76) on the proximal end of
chromosome 25 (BTA25) (Fig. 2A). Visual examination of the SNP
genotypes defined a non-recombinant autozygous interval of
1.15 Mb [Bovine Genome assembly bTau6 (UMD3.1), chr25:
632,647-1,781,139] shared by all 33 cases and encompassing 82
annotated transcripts (Fig. 2B; supplementary material Fig. S1 and
Table S2).
Whole-genome sequencing identifies a likely causative
missense mutation in CLCN7
In the absence of any obvious candidate gene, we decided to
sequence the whole genome of four affected cases, which were
homozygous for the shared identical-by-descent (IBD) segment,
and eight unrelated Belgian Blue controls selected as non-carriers
for the disease haplotype. Individual paired-end libraries (insert
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TRANSLATIONAL IMPACT
Clinical issue
Osteopetrosis is characterized by an increase in bone density owing to
a failure in bone resorption (the breakdown of bone to release minerals
into the bloodstream) by osteoclasts. Severe osteopetrosis is commonly
accompanied by anemia and susceptibility to infections because of
insufficient hematopoiesis in the obliterated medullary cavity and bone
marrow narrowing. Osteopetrosis can be caused by mutations that
impair the generation or the function of osteoclasts. The latter class
comprises mutations in the genes CLCN7 and OSTM1, which encode
the lysosomal Cl–/H+ exchanger ClC-7 and its obligate β-subunit Ostm1,
respectively. In addition to its ubiquitous lysosomal localization, the ClC-
7/Ostm1complex is present at the ‘ruffled border’ of osteoclasts. This
plasma membrane domain is built up by lysosomal exocytosis and
serves to acidify the bone-facing resorption lacunae. Both the formation
of the ruffled border and acid secretion across it might require ClC-
7/Ostm1. Interestingly, dysfunction of lysosomal ClC-7/Ostm1 also
results in a neuronal pathology that cannot be treated by bone marrow
transplantation, the usual treatment for osteopetrosis. Therefore, the
precise function of the ClC-7/Ostm1 complex and its relative contribution
to the pathogenesis of osteopetrosis are important questions.
Results
In this study, the authors used whole-genome sequencing to map a new
CLCN7 mutation that underlies a recessively inherited, severe form of
osteopetrosis in Belgian Blue cattle. Affected calves were mostly
stillborn. X-ray imaging and sectioning revealed that long bones were
hyper-mineralized and fragile as in human patients and in ClC-7/Ostm1-
deficient mice; however, unlike affected humans and mice, the cattle also
presented with large gingival hamartomas (benign tumor-like nodules).
Surprisingly, the mutation was shown to have only a small effect on the
in vivo expression levels and localization of ClC-7/Ostm1. Biophysical
experiments revealed that the mutation did not reduce ion transport;
instead it significantly accelerated the normally slow activation and
deactivation of ClC-7/Ostm1-mediated Cl–/H+ exchange.
Implications and future directions
The authors had found previously that some human disease-causing
CLCN7 mutations accelerate the usually slow voltage-dependent
activation of ClC-7/Ostm1. Because it is unknown whether these
mutations also decrease ClC-7/Ostm1 protein levels in patients, it
remained unknown whether the acceleration of ClC-7 is causative for
osteopetrosis. The present data suggest that indeed not only loss-of-
function, but also faster gating kinetics of ClC-7/Ostm1 might be
deleterious, thereby revealing a new mechanism by which mutations in
ClC-7/Ostm1 lead to disease of lysosomes and bones. It will be
interesting to see whether the different mechanisms by which ClC-
7/Ostm1 dysfunction impairs bone resorption contribute to the
phenotypical variability of human osteopetrosis and why the activation of
ClC-7/Ostm1 ion transport needs to be slow to support normal lysosomal
















size ~250 bp) were generated and ~40 genome-equivalents of
paired-end reads (2×110 bp) were sequenced on an Illumina GAIIx
instrument. Sequence reads were mapped to the bTau6 build using
the Burrows-Wheeler Aligner (BWA) (Li and Durbin, 2009), and
resulting alignments directly visualized with the Integrative
Genomics Viewer (IGV) (Robinson et al., 2011). An average of
~5.4 Gb were uniquely mapped per animal, resulting in a joint ~8-
and ~32-fold coverage of the region of autozygosity in cases and
controls, respectively. DNA sequence variants (DSVs) were called
with SAMtools (Li et al., 2009). We detected 2001 SNPs and 161
indels for a total of 2162 DSVs; 1733 of these (80%) were filtered-
out because they were found in the controls or previously reported
in breeds other than BBCB (W.C., personal communication). Out
of the remaining 429, 111 mapped to transcribed regions, eight to
ORF (Refseq annotation), of which two caused an amino acid
substitution. However, none of these was considered damaging by
Polyphen2 and SIFT programs for protein-sequence-based
prediction of deleteriousness (Adzhubei et al., 2010; Sim et al.,
2012). We further visually scrutinized the entire 1.15 Mb region of
autozygosity. This revealed three sequence reads encompassing a
cluster of three previously undetected nucleotide substitutions
[c2244G >C + c2248T >C + c2250C >A] located in exon 23 of
the CLCN7 gene encoding the anion transport protein ClC-7
(supplementary material Fig. S2). Conventional Sanger sequencing
of five homozygous cases validated the three DSVs (Fig. 3A). Two
of these, [c2248T >C + c2250C >A], jointly cause a tyrosine-to-
glutamine substitution (TAC >CAA: Y750Q), whereas the third
[c2244G >C] is silent (TCG >TCC: S748). The Y750 residue
maps to the second CBS domain (CBS2) of the ClC-7 protein
close to the dimer subunit interface (Fig. 3B). It is highly
conserved between species (Fig. 3C) but not present in the other
eight CLC paralogues (not shown). A position-specific scoring
matrix (PSSM) (Marchler-Bauer et al., 2011) output for the CBS2
domain of the mutant bovine ClC-7 is presented in supplementary
material Fig. S3.
Since the original analysis, we had access to 50 additional whole-
genome sequences of Belgian Blue elite AI sires, of which six were
acknowledged carriers of the causative mutation based on the
occurrence of mutant calves in their progeny and 44 used as control
because they were non-carriers of the disease haplotype. Sequence
reads were mapped as described above and DSVs were called jointly
for affected cases (4), carrier sires (6) and non-carrier sires (44) with
the Genome Analysis Toolkit v2 (McKenna et al., 2010). Within the
defined 1.15-Mb region, among a total of 4829 detected DSVs, only
16 fulfilled the two following criteria: (i) present at homozygous
stage in affected cases, and (ii) present at heterozygous stage in
carrier and absent in control animals. Eight were intergenic, three
intronic and five coding, including the cluster of three CLCN7
substitutions (supplementary material Table S3). The two remaining
coding variants corresponded to one synonymous and one non-
synonymous change. The non-synonymous variant, leading to a
R1023Q in the IFT140 gene, was observed at homozygous stage in
other cattle breeds and predicted benign by Polyphen2 and SIFT.
Thus, the ClC-7 Y750Q stood out as the sole putatively deleterious
mutation on the disease allele.
We developed an assay to directly interrogate the [c2248T >C +
c2250C >A] missense mutations and genotyped the 63 cases, 74 of
their parents, 141 animals from 11 breeds other than BBCB, and
6489 healthy BBCB animals. All cases were homozygous for the
Y750Q mutation, whereas available parents and putative founder
(Gabin) were all carriers. The mutation was absent in the non-
BBCB cohort, and detected at a frequency of 5% (644 carriers) in
BBCB controls. None of the genotyped controls was homozygous
for the mutant (P=0.000026 under Hardy-Weinberg equilibrium).
ClC-7 causality is strengthened by severe osteopetrosis of
affected calves
As mutations in ClC-7 can entail osteopetrosis in humans and mice
[first described in Kornak et al. (Kornak et al., 2001)], we searched
for related clinical symptoms in four newly referred cases shown to
be homozygous for the Y750Q mutation. This revealed a previously
overlooked, severe osteopetrosis of the long bones (Fig. 4). Other
features typical for this condition described in human and mouse
were also noticed in calves, including abnormal skull shape, small
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Fig. 1. Clinical features of congenital hamartomas
in affected Belgian Blue calves. (A) Premature
stillborn calf exhibiting gingival hamartoma, abnormal
skull shape, hydrops and hepatomegaly. Inset shows
livers from mutant (left) and wild-type (right) calves. (B)
Sagittal section of a case head revealing a hamartoma
within the inferior jaw. (C) Dead case presenting a
voluminous hamartoma; note teeth inclusion (arrow).
(D) Alive case with abnormal skull shape accompanied

















body size and visual deficiency or blindness due to retinal
degeneration (listed in supplementary material Table S1). The
striking gingival hamartomas displayed by the majority of mutant
calves might be related to an impaired tooth eruption, which has
been described for ClC-7 knockout mice (Kornak et al., 2001) and
in anecdotal reports of small odontomas in human patients (Luzzi et
al., 2006; Xue et al., 2012). Accordingly, the invariable location of
the hamartoma on the lower jaw may be related to the absence of
canine and incisor teeth on the upper jaw in cattle.
Besides osteopetrosis, ClC-7-deficient mice develop a lysosomal
storage disease and display a progressive neurodegeneration
accompanied by microglial activation and astrogliosis in the central
nervous system (Kasper et al., 2005; Pressey et al., 2010). To test
whether we could find signs pointing to a similar pathology in cattle,
we analyzed protein lysate from the available cerebellum from the
only homozygous Y750Q mutant calf (4 days old) from which we
had tissue samples and compared it to that of a healthy 1-month-old
calf. In this unique ex vivo sample, we detected an increased amount
of the mitochondrial ATP-synthase subunit c (Fig. 5A), which
accumulates as lysosomal storage material in ClC-7-deficient mice
(Kasper et al., 2005). In contrast to Clcn7–/– mice (Kasper et al.,
2005), no increase in cathepsin D levels was detected by
immunoblot (Fig. 5B). Similarly to ClC-7-deficient mice (Wartosch
et al., 2009), the autophagic marker LC3-II was increased in
cerebellum (Fig. 5C) and kidney (not shown) of this one mutant calf
compared to a control calf. Unfortunately, the available tissue was
not suitable for ultrastructural or (immuno)histological analysis, so
that we lack convincing evidence for a lysosomal storage disease.
Taken together, these results – mainly the osteopetrosis in affected
calves – strongly support the causality of the CLCN7 gene.
Protein levels of ClC-7 and Ostm1 are minimally affected by
the Y750Q mutation
Total RNA was extracted from kidney and cerebellum from a
homozygous mutant calf and an age-matched BBCB control. The
RNA was reverse transcribed and three primer pairs (specified in
supplementary material Table S4) were utilized to amplify
overlapping amplicons (541, 1088 and 1256 bp) covering the entire
2427 bp bovine CLCN7 ORF. We did not observe obvious
qualitative or quantitative differences between case and control
amplicons upon agarose gel electrophoresis (data not shown).
Sanger sequencing of the three amplicons confirmed the [c2244G
>C + c2248T >C + c2250C >A] nucleotide substitutions as the
only differences (data not shown).
ClC-7 protein destabilization by a disease-causing mutation has
previously been reported in a human case (Kornak et al., 2001). To
investigate whether the bovine Y750Q mutation might similarly affect
ClC-7 stability, we analyzed membrane protein extracts from kidney
(Fig. 6A) and cerebellum (not shown) of wild-type and mutant calves
by immunoblotting against ClC-7. In both types of tissue, we
observed only a modest reduction in ClC-7 concentration in the
mutant calf. Additionally, apart from the main ClC-7 band there are
minor bands at ~60 kDa and ~85 kDa of unknown nature in the wild-
type lysate that are strongly reduced in the mutant. It seems very
unlikely that these differences cause the observed severe osteopetrotic
phenotype of mutant calves because heterozygous Clcn7+/– mice
display no phenotype (Kornak et al., 2001). Also, for the β-subunit of
ClC-7, Ostm1, only subtle differences were detected, such as the
stronger staining of a smear close to ~66 kDa (Fig. 6B). We did not
observe large changes in overall levels of either the endoplasmic
reticulum (ER) precursor form or of the predominant processed form.
By contrast, Ostm1 levels are drastically reduced in mice lacking ClC-
7 (Lange et al., 2006) (Fig. 6B). To test whether changes in protein
levels might be observed in heterologous expression, we inserted the
corresponding mutation into an available rat ClC-7 expression vector
(Y744Q in rat ClC-7) and transfected HeLa cells with Ostm1 and
either wild-type or mutant ClC-7. Western blots of protein lysate from
these cells revealed only subtle differences for ClC-7 and Ostm1, in
stark contrast to the absence of the processed form of Ostm1 when it
was overexpressed without ClC-7 (supplementary material Fig. S4).
The Y750Q mutation does not abolish the functional
interaction between ClC-7 and Ostm1 or their co-trafficking
to lysosomes
Some human osteopetrosis-causing CLCN7 mutations impair
trafficking of ClC-7, resulting in retention of the mutant protein in
the ER (Leisle et al., 2011; Schulz et al., 2010). We evaluated
potential effects of the Y750Q mutation on the subcellular
targeting of heterologously expressed ClC-7. Upon transfection in
HeLa cells, mutant ClC-7 was correctly targeted to lysosomes as
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Fig. 2. Genome-wide association mapping for the
hamartoma disease locus. (A) Manhattan plot for
case/control GWAS presenting a unique genome-
wide significant signal on chromosome 25; the 29
autosomes are alternately labeled in gray or black.
inset shows a typical hamartoma case. (B) Cases
genotypes for 1256 chromosome 25 SNP;
homozygous genotypes are shown in yellow or white,
heterozygous genotypes in red; the centromeric 1.15-
Mb homozygosity region, identical by state among all
















was the wild-type ClC-7 (Fig. 7A). Ostm1, which is required for
protein stability and the Cl–/H+ exchange activity of ClC-7 (Lange
et al., 2006; Leisle et al., 2011), needs binding to ClC-7 for ER
export and targeting to lysosomes (Lange et al., 2006; Stauber and
Jentsch, 2010). To test whether the Y750Q mutation affects ClC-
7/Ostm1 interaction or Ostm1 trafficking to lysosomes, wild-type
and mutant ClC-7 expression vectors were co-transfected with
Ostm1 that was labeled by a green-fluorescent protein (GFP) fused
to its C-terminus. Immunohistochemistry of transfected cells using
antibodies directed against the late endosomal/lysosomal marker
protein LAMP-1 showed that Ostm1 trafficks with both wild-type
and mutant ClC-7 to lysosomes, whereas Ostm1-GFP remains in
the ER when expressed without ClC-7 (Fig. 7B). Furthermore,
immunoblots of kidney membrane protein lysate against Ostm1
showed that the bulk of Ostm1 was proteolytically processed to its
mature ~30 kDa form, with only subtle difference between wild-
type and affected calves (Fig. 6B). Because cleavage occurs in or
on the way to lysosomes (Lange et al., 2006), this finding provides
support for correct in vivo targeting of Ostm1. This was confirmed
by western blot analysis of overexpressed Ostm1, which can be
detected at similar levels in its processed form when coexpressed
with wild-type or mutant ClC-7, but not when overexpressed alone
(supplementary material Fig. S4). Thus, the Y750Q mutation does
not inhibit the ClC-7/Ostm1 interaction or its ClC-7-dependent
trafficking to lysosomes.
The Y750Q mutation accelerates the gating of ClC-7/Ostm1
We next assessed the effect of the Y750Q mutation on ion transport
by ClC-7/Ostm1. We made use of a human ClC-7 construct that is
partially mislocalized to the plasma membrane (hence referred to as
ClC-7PM) due to the disruption of two dileucine-based endosomal
sorting motifs (Stauber and Jentsch, 2010). The biophysical
characteristics of this surface-expressed mutant can be conveniently
analyzed in Xenopus oocytes by two-electrode voltage-clamp
recording (Leisle et al., 2011). ClC-7PM/Ostm1 mediates outwardly
rectifying currents that are slowly gated by voltage (Leisle et al.,
2011). Introduction of the mutation corresponding to Y750Q
(Y746Q) did not reduce the current amplitude and had no detectable
effect on the outwardly rectifying voltage dependence of ClC-
7PM/Ostm1 (Fig. 8A,B). However, it accelerated the voltage-
dependent activation and relaxation kinetics more than threefold
(Fig. 8A,C), with an activation rate constant at +80 mV of
104±6 milliseconds for the Y746Q mutant versus
341±18 milliseconds for ‘wild-type’ human ClC-7PM/Ostm1 (mean
values ± s.e.m. from 17 and 13 oocytes, respectively, from three
independent batches of oocytes).
DISCUSSION
Identification of the disease-causing gene and mutation
Our previous identifications of genes and mutations underlying
various syndromes in BBCB (Charlier et al., 2008; Fasquelle et al.,
2009; Sartelet et al., 2012a; Sartelet et al., 2012b) were mainly
facilitated by the use of medium-density SNP chips for bovine
samples. In human genetics, molecular elucidation of monogenic
disorders has benefited tremendously from next generation
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Fig. 3. Missense mutations in the second CBS domain of the ClC-7
protein. (A) Sequence traces of CLCN7 exon 23 for wild-type (top) and
mutant (bottom) calves; triangles pinpoint three nucleotide substitutions with
the corresponding Y750Q amino acid mutation in red. (B) X-ray structure of
CmCLC displaying the localization of the mutated amino acid (red spheres in
either subunit of the dimer) according to the published alignment between
CmCLC and ClC-7 (Feng et al., 2010). The transmembrane core-forming
parts are depicted in gray, the cytosolic domains CBS1 in yellow and CBS2 in
green, using darker colors for one subunit. (C) ClC-7 CBS2 domain
alignment, from mammals to fish, showing its conservation through evolution
with the Y750Q mutation in red.
Fig. 4. Severe osteopetrotic phenotype exhibited by Y750Q
homozygous calves. (A) Dorsoventral radiographs of extended hind legs of
a one-week-old homozygous mutant calf (MUT, right) and an age-matched
Belgian Blue control calf (WT, left) are presented. X-rays were performed
using a digital radiograph system [Vertix Vet (150 kV/600 mA), Siemens,
Germany] with 75 kV and 100 mA as technical parameters. The bone marrow
cavity is clearly visible within metatarsus of the wild-type calf but absent from
the mutant corresponding bone (red arrows). The mutant calf also exhibits a
tibia fracture (white arrow) probably consecutive to the acknowledged
increased fragility of osteopetrotic long bones. (B) Fresh transversal (left) and
sagittal (right) sections of long bones (tibia) of age-matched mutant (MUT)


















sequencing (NGS), either in combination with whole-exome capture
or targeted capture of specific genomic regions, or used to directly
sequence the entire genome (WGS) (Lupski et al., 2010; Ng et al.,
2009; Volpi et al., 2010). Whole-exome sequencing was also
successfully employed to identify a human CLCN7 mutation in
osteopetrosis patients (Sui et al., 2013). Until recently, targeted
capture of specific genomic regions was seriously hampered in cattle
as a result of the suboptimal quality of the reference genome;
exome-capturing reagents were not yet available. We therefore
elected to use WGS to tentatively speed up the final positional
cloning step. Indeed, even if more costly, WGS was thought to
generate extremely valuable ‘byproducts’, including breed-specific
catalogues of common polymorphisms that could be used to filter
out non-causative variants (Charlier et al., 2012). Along the same
line, WGS can be mined to identify variants that are predicted to
disrupt gene and/or protein function. These include splice site
variants, frame-shift mutations, nonsense mutations and missense
mutations predicted to be disruptive. Depending on their frequency,
some of them could negatively affect the fitness of the breed. WGS
also uncovered thousands of non-synonymous variants, of which a
number are bound to influence traits of economic importance. These
non-synonymous variants could be directly usable by breeding
organizations in genomic selection.
We identified three private base-pair substitutions in exon 23 of
the CLCN7 gene, for which affected calves were homozygous.
These mutations lie within a 7-bp segment. They most probably
originated from a unique mutational event, possibly in the germline
of one of the parents of the common ancestor to whom we could
trace back all 63 affected calves. Indeed, it was recently shown
(Schrider et al., 2011) that up to 3% of de novo mutations in the
germline are part of a multinucleotide mutational event (MME).
Since mapping the gene underlying the severe pathology of the
calves in 2009, we first developed an indirect, haplotype-based
diagnostic test. After the identification of the mutation in 2010, we
established a direct test to detect carriers among artificial
insemination sires. The successive exploitation of these tests to
avoid carrier mating immediately dropped the number of mutant
births (supplementary material Fig. S5). The mutation-based
diagnostic test has been integrated into the BBCB breeding scheme
and is now systematically used to assess carrier-free status before
allowing registration of new artificial insemination sires. More
than 15,000 animals, mainly males, were genotyped to exclude
carrier bulls from breeding and this contributed to reduce the
carrier frequency from 13% in 2009 to ∼6% nowadays
(supplementary material Fig. S5). Retrospective evaluation of the
indirect test performance on 500 animals reanalyzed with the
mutation-based test identified a single false positive (haplotype
identical to the disease haplotype based on markers but without the
mutation) and no false negatives (carrier of the mutation on a
recombinant haplotype). It further demonstrated the practical
interest of developing an indirect diagnostic test while hunting for
the causative mutation. In the Belgian Blue cattle breed, diagnostic
test diffusion, currently for seven recessive diseases, has directly
influenced calf mortality rate (before 6 months), lowering it from
11% in 2006 to an estimated 7% in 2012. This reduction has had
a huge economic impact that is widely recognized by breeders and
veterinarians. However, due to the avoidance of carrier mating, we
unfortunately lacked tissue from more mutant calves for further
analysis. For example, we had no brain sample that could be
processed for histological analysis.
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Fig. 5. Lysosomal storage in a homozygous ClC-7(Y750Q)
calf. Lysates (60 µg protein per lane) of cerebellum from a
control calf (WT) and from a calf homozygous for the Y750Q
mutation (MUT) were analyzed by immunoblot against the
indicated proteins. Immunoblotting for α-tubulin served as
loading control. (A) Levels of subunit c of the mitochondrial
ATP synthase were increased in the mutated calf. (B) The
animals displayed no differences in the levels of the
preprocathepsin D (immature) or the intermediate and mature
forms of cathepsin D. (C) The autophagic marker LC3-II was
increased in the mutated calf whereas overall LC3 levels were
unchanged.
Fig. 6. Protein levels of ClC-7 and Ostm1. Membrane protein-enriched
lysates (80 µg per lane) of kidney from a control calf (WT) and a calf
homozygous for the Y750Q mutation (MUT), as well as from a Clcn7–/–
mouse (KO) and its wild-type littermate (WT) were analyzed by western blot
for ClC-7 (A) and Ostm1 (with an antibody directed against a C-terminal
epitope that also recognizes the proteolytically processed transmembrane
fragment) (B). Immunoblotting for α-tubulin served as loading control. Lack of
ClC-7 signal in lysate from the Clcn7–/– mouse shows the specificity of the
antibody. Ostm1, which migrates with an apparently higher molecular weight
in the bovine samples, exists predominantly in its proteolytically processed
form (~30 kDa). The different sizes could be due to species-specific















Osteopetrotic phenotype of the mutant calves
Osteopetrosis has been observed in various cattle breeds. The
affected calves are generally born premature (mostly stillborn).
Common phenotypes include an abnormal skull shape, inferior
brachygnatia (shortened mandible) and a protruding tongue, features
also observed with the calves homozygous for the CLCN7 mutation.
Recently, a deletion mutation in the SLC4A2 gene, encoding the
anion exchanger AE2, has been found to underlie osteopetrosis in
Red Angus cattle (Meyers et al., 2010). By mediating Cl–/HCO3–
exchange across the basolateral membrane, AE2 leads to acid uptake
into the cytosol (Coury et al., 2013; Wu et al., 2008), which is then
extruded by the H+-ATPase of the ruffled border into the resorption
lacuna. ClC-7 is thought to enable proton pumping by providing an
electric shunt for the proton pump (Kornak et al., 2001). In addition,
ClC-7 might be required for the exocytic insertion of proton pumps
and other constituents of lysosomal membranes into the ruffled
border (Stauber and Jentsch, 2013), a notion supported by the
underdevelopment of the ruffled border observed in Clcn7–/– mice
(Kornak et al., 2001). The hepatomegaly found in most affected
calves can be explained by an extramedullary blood production
secondary to the osteopetrotic obliteration of the bone marrow
cavity (Tolar et al., 2004), and – as mentioned above – the
hamartomas could result from the lack of tooth eruption
accompanying the osteopetrosis.
A physiological function of slow gating?
Like several human osteopetrosis-associated CLCN7 mutations
(Leisle et al., 2011), the present bovine CLCN7 mutation drastically
accelerated ClC-7/Ostm1 gating. The acceleration by a factor of
about three is comparable with that of other mutations that
accelerate ClC-7/Ostm1 gating by a factor between ~2.5 and >5
(Leisle et al., 2011; Ludwig et al., 2013) and is clearly stronger than
the less-than-twofold acceleration by a recently identified human
ClC-7 mutation causative for osteopetrosis (Barvencik et al., 2013).
Most of those mutations affected residues that might interfere with
contacts of cytosolic CBS domains and the ClC-7 transmembrane
block (Leisle et al., 2011). We have recently shown that the slow
gating kinetics of ClC-7/Ostm1 is based on the common gating of
both dimer subunits, which depends on the cytosolic C-terminus
(Ludwig et al., 2013). The mutation identified in this study localizes
in CBS2 close to the interface with the CBS2 domain of the other
ClC-7 subunit and might impinge on the common gating
mechanism. None of these mutations significantly altered the
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Fig. 7. Correct subcellular targeting of ClC-7/Ostm1 upon heterologous
expression. (A) After transient transfection with rat ClC-7, either wild-type
(WT) or the Y744Q mutant (MUT), HeLa cells were immunolabeled for ClC-7
(green in overlay) and the late endosomal/lysosomal marker protein LAMP-1
(red); blue in overlay indicates DAPI staining of nuclei. (B) HeLa cells co-
transfected with rat ClC-7 (either WT or MUT) and mOstm1-GFP (green in
overlay), or with Ostm1-GFP alone (bottom panel) were immunolabeled for
ClC-7 (red) and the late endosomal/lysosomal marker protein LAMP-1 (blue).
Fig. 8. Accelerated gating of ClC-7/Ostm1 by the disease-causing
mutation. Xenopus oocytes coexpressing Ostm1 and partially plasma
membrane-localized hClC-7PM, either without further mutation (‘WT′) or
carrying the Y746Q mutation (MUT), were recorded in a two-electrode
voltage clamp. (A) Current traces (representative for three batches of
oocytes) recorded with the clamp protocol shown on the right (holding
potential −30 mV, subsequent 2-second test pulses between −80 mV and 80
mV in 20-mV intervals, each followed by a 0.5-second deactivation pulse at
−80 mV) are shown as superimposition for ‘WT′ and MUT. Activation (black
arrows, quantified in C) and relaxation kinetics (white arrows) of the currents
were accelerated by the Y746Q mutation. Scales for the time and intensity of
the current traces are shown on the right (the clamp protocol is not shown in
scale). (B) Mean currents after 2 seconds were normalized to the current at
+80 mV and plotted as function of voltage. Values are the mean of 13 (‘WT′)
and 18 (MUT) oocytes from three batches of oocytes, small error bars
(s.e.m.) are hidden behind the symbol. (C) Rate constants of current
activation were determined by a single exponential fit of the current trace
during the first 250 milliseconds of depolarization to 80 mV for each of the
measured oocytes. Thick lines in data point clouds indicate the arithmetic


















voltage-dependence of the currents or the subcellular localization in
heterologous expression systems (Barvencik et al., 2013; Leisle et
al., 2011). These observations suggest that the unique slow kinetics
of voltage-activation of ClC-7/Ostm1 might be crucial for its cellular
function. However, before drawing this conclusion it must be
ascertained that these mutations do not change the abundance,
localization or other properties of ClC-7 in vivo.
Acceleration of ClC-7 gating kinetics has been found with
mutations identified both in autosomal recessive osteopetrosis
(ARO) and in autosomal dominant osteopetrosis type 2 (ADO2)
(Leisle et al., 2011). ADO2 patients present a mild osteopetrosis that
becomes apparent in adulthood. Because heterozygous Clcn7+/–
mice suggest that osteopetrosis cannot be caused by CLCN7 haplo-
insufficiency, these mutations are likely to exert a dominant effect.
Dominance could result for example by ER retention of a wild-
type/mutant heterodimer, which could reduce ClC-7 activity down
to 25%. It might also be explained by a weak gain-of-function effect
(more current after short times of depolarization due to accelerated
gating) that would be fully expressed in mutant/mutant homodimers
that are expected to account for 25% of total ClC-7 dimers in
heterozygous patients, but would be less pronounced in the expected
50% wild-type/mutant heteromers because the presence of an
attached wild-type subunit reduces the gating kinetics of the fast
mutants (Ludwig et al., 2013). Obviously, for either mechanism (ER
retention or gain of current) the same mutation will have more
severe effects when present on both alleles.
Although the acceleration of ClC-7/Ostm1 that we observed
previously with several pathogenic human mutations (Leisle et al.,
2011) is intriguing, we could not exclude the possibility that these
mutations caused osteopetrosis by reducing ClC-7 protein levels in
vivo. So far, we had protein data only for one such accelerating
mutant (human ClC-7R762Q) (Leisle et al., 2011), which showed that
the mutant protein is unstable in patient-derived fibroblasts (Kornak
et al., 2001). Here we show for the first time that a ‘fast’
osteopetrosis-causing ClC-7 mutant displays near-normal expression
levels and lysosomal localization in native tissues, strengthening the
case for a pathogenic role of accelerated gating. However, it remains
unclear how such ‘gain-of-function’ mutations might cause very
similar, if not identical phenotypes as a loss-of-function, as observed
with Clcn7–/– mice and several human mutations.
The related endosomal Cl–/H+ exchangers ClC-3 through ClC-6
display much faster gating kinetics, with a large current component
being instantaneously present upon depolarization (Friedrich et al.,
1999; Li et al., 2000; Neagoe et al., 2010). It remains to be clarified
whether the voltage dependence of intracellular CLCs is the same on
their native compartments as at the plasma membrane, where they can
be analyzed. An outwardly rectifying ClC-7/Ostm1 should be largely
inactive at the reported inside-positive voltage of lysosomes
(Koivusalo et al., 2011; Leisle et al., 2011). Reductionist model
calculations of vesicular acidification, however, predict an inside-
negative voltage generated by pH gradient-driven Cl– import (Weinert
et al., 2010). The importance of slow ClC-7/Ostm1 gating suggests
that the exchanger should be inert to relatively quick voltage
transitions, which could be envisaged upon triggered release of
luminal calcium or during fusion processes with endosomal
compartments. To further approach this interesting issue, new tools to
monitor lysosomal voltage and ClC-7/Ostm1 activity will be required.
Because ion transport by ClC-7/Ostm1 will affect lysosomal ion
homeostasis in general and the voltage and osmolarity of this
compartment in particular (Stauber and Jentsch, 2013), it remains to
be elucidated how an acceleration of the ClC-7/Ostm1 gating
impinges upon these parameters.
MATERIALS AND METHODS
Genome-wide haplotype-based association study
DNA extraction and SNP genotyping using a custom-made bovine 50K SNP
array were conducted using standard procedures as described (Charlier et
al., 2008). Haplotypes were reconstructed using Beagle (Browning and
Browning, 2007). DualPHASE was then used to assign haplotypes to ten
hidden haplotype states (ancestral haplotypes) (Druet and Georges, 2010).
Genome-wide association mapping was performed using GLASCOW
(Zhang et al., 2012): association between the hidden haplotype states and
the phenotype was tested using a generalized linear mixed model (with a
logit link function) including a polygenic effect accounting for stratification.
The genomic relatedness among individuals was estimated on the basis of
hidden haplotype state similarity.
Genome-wide resequencing
Four affected individuals homozygous for the defined IBD haplotype were
selected, as well as eight unrelated individuals from the same breed,
genotyped as non-carriers of the disease haplotype. To minimize the
sequencing cost and maximize the putative applied outcome, the eight
control individuals were chosen as being homozygous mutant for two
additional distinct recessive diseases (four mutants each) for which the
chromosomal location was known but the causative genes and mutations
were still to be found. The Pair-End Library Prep Kit v2 from Illumina was
used to generate a ∼200-250 bp paired-end sequencing library from
genomic DNA fragments for each animal. Briefly, total genomic DNA was
extracted and fragmented by sonication (Bioruptor, Diagenode). Size-
selected fragments were end-repaired and ligated to Illumina Paired-End
sequencing adapters. Each library was sequenced on one lane of the flow-
cell of an Illumina GAIIx with the paired-end module to generate high-
quality reads (2×110 bp). Reads were mapped and analyzed with publicly
available software: Burrows-Wheeler Alignment Tool (http://bio-
bwa.sourceforge.net) and SAMtools (http://samtools.sourceforge.net). The
output files were readily uploaded in the Integrative Genomics Viewer
(IGV) (Robinson et al., 2011) and visually scrutinized for private variation.
Mutation validation at the DNA and mRNA levels
A primer pair (gUP1-gDN1) was designed to amplify a PCR product
encompassing the three private SNP identified by NGS (supplementary
material Table S4). It was used to amplify products from genomic DNA of
homozygous cases, carriers and unaffected unrelated individuals using standard
procedures. Amplicons were directly sequenced using the Big Dye terminator
cycle sequencing kit (Applied Biosystems, Foster City, CA). Electrophoresis
of purified sequencing reactions was performed on an ABI PRISM 3730 DNA
analyzer (PE Applied Biosystems, Foster City, CA). Sequence traces were
aligned and compared with bovine reference using the Phred/Phrap/Consed
package (www.phrap.org/phredphrapconsed.html). Total RNA was extracted
from kidney of one homozygous case and one unaffected unrelated individual
using Trizol (Invitrogen). The obtained RNA was treated with TurboDNaseI
(Ambion) and cDNA was synthesized using SuperscriptTMIII First Strand
Synthesis System for RT-PCR (Invitrogen). Full length CLCN7 cDNA was
amplified using three specific primer pairs (cUP1-cDN1, cUP2-cDN2, cUP3-
cDN3) (supplementary material Table S4) and the three overlapping amplicons
were directly sequenced and analyzed as describe above.
Development of a genotyping test for the missense mutation
A 5′ exonuclease assay (Taqman) was developed to genotype the [c2248T
>C + c2250C >A] CLCN7 mutations, using 5′-CCATGGACCTGT -
CTGAGTTCAT-3′ and 5′-ACCCCCCAGCAGTACCT-3′ as PCR primer
pair combined with 5′-CCC[TAC]ACGGTGCCC-3′ (wild type) and 5′-
CC[CAA]ACGGTGCCC-3′ (mutant), respectively, labeled with VIC and
FAM as Taqman probes. Allelic discrimination reactions were carried out
on an ABI7900HT instrument (Applied Biosystems, Foster City, CA) using
standard procedures.
Western blotting
Tissues from calves and mice (kidney or cerebellum) were homogenized in
HEPES-buffered saline (HBS, pH 7.4) with protease inhibitors (complete
















protease inhibitor cocktail, Roche) and cleared by two successive
centrifugation steps at 1000 g for 10 minutes. Membrane protein fractions
were prepared by centrifugation at 100,000 g for 30 minutes and subsequent
resuspension in HBS supplemented with 2% (w/v) SDS. Membrane protein
fraction (80 µg per sample) or whole-organ lysate (60 µg per sample) were
separated by SDS-PAGE and transferred to nitrocellulose. ClC-7 was
detected with a polyclonal rabbit antibody directed against the C-terminal
peptide RFPPIQSIHVSQDEREC (100% conserved between murine and
bovine ClC-7 protein). The other primary antibodies were guinea-pig anti-
Ostm1 (Lange et al., 2006), rabbit antibodies against subunit c of the
mitochondrial ATP synthase (a gift from Eiki Kominami, Juntendo
University, Tokyo, Japan), cathepsin D (Calbiochem) and LC3B (Cell
Signaling), and a mouse antibody against α-tubulin (clone DM1A, Sigma).
After incubation with secondary antibodies conjugated to horseradish
peroxidase (Jackson ImmunoResearch), chemiluminescence signal was
detected with a camera system (PeqLab).
Expression constructs
Constructs for expression of rat ClC-7 (Kornak et al., 2001) and of
fluorescently tagged Ostm1-GFP (Stauber and Jentsch, 2010) in cell culture
were as described. Constructs in pTLN for the expression of partially cell
surface-localized human ClC-7L23A,L24A,L68A,L69A (hClC-7PM) and Ostm1 in
Xenopus oocytes, were described previously (Leisle et al., 2011). Point
mutations were introduced by PCR and the complete ORF of all constructs
were confirmed by sequencing.
Subcellular targeting and interaction with Ostm1
HeLa cells were transfected with plasmid DNA encoding the respective
construct(s) using FuGENE6 (Roche). ClC-7 with Ostm1-GFP constructs
were co-transfected at a 50:1 (ClC-7:Ostm1-GFP) weight ratio to prevent
expression of excess Ostm1-GFP, which would not be exported from the
ER. Cells were grown for 26-28 hours before fixation with 4% PFA in PBS
for 15 minutes. After incubation with 30 mM glycine in PBS for 5 minutes,
cells were incubated sequentially with primary and secondary antibodies in
PBS containing 0.1% saponin supplemented with 5% BSA. Each incubation
was for 1 hour at room temperature. Primary antibodies were rabbit anti-
ClC-7 (7N4B) (Kornak et al., 2001), and mouse anti-Lamp-1 (clone H4A3;
from the DSHB). Secondary antibodies conjugated to AlexaFluor 488, 546
or 633 were from Molecular Probes. Images were acquired with an LSM510
confocal microscope with a 63×, 1.4 NA oil-immersion lens (Zeiss).
Two-electrode voltage clamp measurements
Current measurements of ClC-7PM/Ostm1 were performed as described
(Leisle et al., 2011). Xenopus laevis oocytes were injected with cRNA
encoding for the hClC-7PM construct and for Ostm1 (23 ng each), which was
transcribed with the mMessage Machine Kit (Ambion) after linearizing of
the pTLN plasmid with MluI. After 3 days incubation in ND96 saline
(96 mM NaCl, 2 mM K-gluconate, 1.8 mM Ca-gluconate, 1 mM Mg-
gluconate and 5 mM HEPES, pH 7.5) at 17°C, currents were measured in
ND96 using a standard two-electrode voltage clamp at room temperature,
employing a TurboTEC amplifier (npi electronic) and pClamp10.2 software
(Molecular Devices). The holding potential was −30 mV. Test pulses of
2 seconds between −80 and +80 mV (in 20-mV steps) were followed by a
0.5-second deactivation pulse at −80 mV. Rate constants of the activation
kinetics were determined by fitting the currents of the first 250 milliseconds
of depolarization to +80 mV to a single-exponential function.
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SUPPLEMENTARY MATERIAL  
 
Table S1.  Summary of clinical symptoms.  The clinical symptoms for the 63 cases are 





































































































































1 F 12 small dead yes yes 3 cm yes - yes yes yes yes - 
2 F 0 normal dead yes yes 4 cm - - yes yes yes yes - 
3 M 0 normal dead yes yes 10 cm - - yes yes no yes - 
4 F 15 small dead yes yes 10 cm - - yes yes yes yes - 
5 M 30 small dead yes yes 7 cm - - yes yes yes yes - 
6 F 0 small alive yes yes 5 cm no yes no no no no - 
7 F 0 normal alive yes yes 2 cm no yes no no no no - 
8 F 0 normal alive yes yes 3 cm yes yes no no no no - 
9 F - - dead yes yes yes - - - - - - - 
10 - 0 small dead yes yes 5 cm - - yes yes yes yes - 
11 F 0 small dead yes yes 12 cm - - yes yes yes yes - 
12 F 0 small alive yes yes no yes yes no no no no - 
13 M 0 normal alive yes yes no yes yes - - - - - 
14 M 31 small dead yes yes 10 cm - - yes yes yes yes - 
15 F 0 normal alive yes yes 2 cm yes yes no - - no - 
16 F 15 small dead yes yes 10 cm - - yes yes yes yes - 
17 M 0 normal alive yes yes 12 cm yes yes no no no yes - 
18 F 16 small dead yes yes 6 cm - - yes yes yes yes - 
19 M 0 small alive yes yes no yes yes no - - no - 
20 M - small dead yes yes 7 cm - - yes yes yes yes - 
21 M - small dead yes yes 2 cm - - yes yes yes yes - 
22 F - small dead yes yes 10 cm - - yes yes yes yes - 
23 F - - dead yes yes yes - - yes - - yes - 
24 M 0 normal dead yes yes 3 cm - - yes yes no no - 
25 M 60 small dead yes yes 5 cm - - yes yes yes yes - 
26 M 0 normal dead yes yes yes - - - - - yes - 
27 M 0 normal dead yes yes yes - - - - - - - 
28 F - - dead yes yes yes - - - - - - - 
29 M 30 small dead yes yes yes - - yes - - yes - 
30 F 21 small dead yes yes 4 cm - - yes yes yes yes - 
31 M 0 normal alive yes yes 3 cm - yes no - - no - 
32 M - - dead yes yes yes - - - - - - - 
33 F 7 small dead yes yes 10 cm - - yes yes yes yes - 
34 M 0 normal dead yes yes yes - - yes - - yes - 
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35 M - - dead yes yes yes - - - - - - - 
36 M 0 normal alive yes yes no - yes no - - no - 
37 M 15 small dead yes yes 1 cm - - yes - - yes - 
38 - 0 normal alive yes yes no no yes no - - no - 
39 - 0 normal alive yes yes no yes yes no - - no - 
40 - - - dead yes yes yes - - - - - - - 
41 F 30 small dead yes yes 4 cm - - yes yes yes yes - 
42 - - - dead yes yes yes - - - - - - - 
43 - 0 normal dead yes yes yes - - no - - no - 
44 - 0 small dead yes yes 10 cm - - yes yes no yes - 
45 M 0 normal alive yes yes no - yes no - - no - 
46 - - - dead yes yes yes - - - - - - - 
47 - 0 normal alive yes yes no yes yes no - - no - 
48 - - - dead yes yes yes - - - - - - - 
49 F 0 small dead yes yes 10 cm - - no - - no - 
50 M 0 normal dead yes yes 2 cm - - no - - no - 
51 M 30 small dead yes yes 5 cm - - yes - - yes - 
52 - - - dead yes yes yes - - - - - - - 
53 - - - dead yes yes yes - - - - - - - 
54 M 0 normal alive yes yes no yes yes no - - no - 
55 M 0 normal dead yes yes yes - - yes - - yes - 
56 F 0 normal dead yes yes yes - - yes - - yes - 
57 F 0 normal dead yes yes yes - - yes - - yes - 
58 M 0 normal alive yes yes yes - yes no - - no - 
59 M 0 normal dead yes yes yes - - yes - - yes - 
60 F 0 normal alive yes yes yes yes yes no yes no no yes 
61 M 0 small dead yes yes no - - - yes - - yes 
62 M 0 normal alive yes yes no yes yes no yes no no yes 
63 F 0 normal dead yes yes no yes - yes yes no yes yes 
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Figure S1.  Gene content of the non-recombinant autozygous interval.  Screen capture of the 
Ensembl Genome Browser (http://www.ensembl.org/Bos_taurus/Info/Index) displaying the 82 
annotated bovine transcripts in the corresponding 1.15 Mb region. 
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Table S2.  List of annotated transcripts the 1.15 Mb non-recombinant autozygous interval 
on BTA25.   The list of 82 transcripts was downloaded from the Ensembl Genome Browser web 
site (http://www.ensembl.org/Bos_taurus/Info/Index).  Gene coordinates are given for bovine 
genome assembly UMD3.1.  The CLCN7 gene is highlighted in red.   
 
Start (bp) End (bp) Str Name Transcript ID Description 
627456 633977 -1 NARFL ENSBTAT00000003225 Cytosolic Fe-S cluster assembly factor NARFL  [Source:UniProtKB/Swiss-Prot;Acc:A4FV58] 
649253 652835 1 MSLN ENSBTAT00000000202 mesothelin precursor  [Source:RefSeq peptide;Acc:NP_001093844] 
653105 660655 -1 MSLNL ENSBTAT00000047719 Uncharacterized protein  [Source:UniProtKB/TrEMBL;Acc:F1MQ52] 
665058 668257 -1 RPUSD1 ENSBTAT00000000204 
RNA pseudouridylate synthase domain-containing 
protein 1  [Source:UniProtKB/Swiss-
Prot;Acc:Q17QT4] 
668529 676616 1 CHTF18 ENSBTAT00000026311 
chromosome transmission fidelity protein 18 
homolog  [Source:RefSeq 
peptide;Acc:NP_001179389] 
676665 677047 -1 GNG13 ENSBTAT00000026313 
guanine nucleotide-binding protein G(I)/G(S)/G(O) 
subunit gamma-13  [Source:RefSeq 
peptide;Acc:NP_001193261] 
724446 775899 -1 LMF1 ENSBTAT00000004206 Lipase maturation factor 1  [Source:UniProtKB/Swiss-Prot;Acc:Q0P5C0] 
787493 790981 1 SOX8 ENSBTAT00000027633 Uncharacterized protein  [Source:UniProtKB/TrEMBL;Acc:F1MBL5] 
857167 858273 1 SSTR5 ENSBTAT00000052225 Somatostatin receptor type 5  [Source:UniProtKB/Swiss-Prot;Acc:F1MV99] 
865752 867111 -1 C1QTNF8 ENSBTAT00000016731 Uncharacterized protein  [Source:UniProtKB/TrEMBL;Acc:E1BF11] 
871131 877122 -1 TEKT4 ENSBTAT00000016726 Tektin-4  [Source:UniProtKB/Swiss-Prot;Acc:Q2TA38] 
959758 984950 1 CACNA1H ENSBTAT00000012991 Uncharacterized protein  [Source:UniProtKB/TrEMBL;Acc:F1MQV2] 
987390 989247 -1 TPSB1 ENSBTAT00000009636 TPSB1 protein; Uncharacterized protein  [Source:UniProtKB/TrEMBL;Acc:A6QPI9] 
994572 996276 1 TPSB1 ENSBTAT00000037579 tryptase beta-2 precursor  [Source:RefSeq peptide;Acc:NP_776627] 
1006912 1008669 -1 BT.88628 ENSBTAT00000066317 Uncharacterized protein  [Source:UniProtKB/TrEMBL;Acc:G3MXR7] 
1017616 1022334 -1  ENSBTAT00000063348 Uncharacterized protein  [Source:UniProtKB/TrEMBL;Acc:G3MYJ4] 
1041085 1048106 1 UBE2I ENSBTAT00000056739 SUMO-conjugating enzyme UBC9  [Source:RefSeq peptide;Acc:NP_001092842] 
1048611 1048737 -1  ENSBTAT00000063629   
1054501 1066815 1 BAIAP3 ENSBTAT00000018748 Uncharacterized protein  [Source:UniProtKB/TrEMBL;Acc:F1MNU6] 
1067758 1070205 -1 C25H16ORF42 ENSBTAT00000018749 
probable ribosome biogenesis protein C16orf42 
homolog  [Source:RefSeq 
peptide;Acc:NP_001092381] 




1082676 1113094 -1 UNKL ENSBTAT00000018773 Uncharacterized protein  [Source:UniProtKB/TrEMBL;Acc:F1MNI6] 
1116677 1117637 -1 CCSMST1 ENSBTAT00000047510 Protein CCSMST1  [Source:UniProtKB/Swiss-Prot;Acc:Q1ECT8] 
1126769 1133966 -1 CCDC154 ENSBTAT00000000741 Uncharacterized protein  [Source:UniProtKB/TrEMBL;Acc:F1MS01] 
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1135571 1156102 -1 CLCN7 ENSBTAT00000021122 H(+)/Cl(-) exchange transporter 7  [Source:UniProtKB/Swiss-Prot;Acc:Q4PKH3] 
1159757 1163098 -1 PTX4 ENSBTAT00000006786 Uncharacterized protein  [Source:UniProtKB/TrEMBL;Acc:E1B8G2] 
1167351 1168312 1  ENSBTAT00000049975   
1172266 1181534 1 TELO2 ENSBTAT00000025412 Uncharacterized protein  [Source:UniProtKB/TrEMBL;Acc:E1B7I8] 
1182105 1237269 -1 IFT140 ENSBTAT00000047406 Uncharacterized protein  [Source:UniProtKB/TrEMBL;Acc:E1B860] 
1194760 1207350 1 TMEM204 ENSBTAT00000009534 Transmembrane protein 204  [Source:UniProtKB/Swiss-Prot;Acc:Q0IIE5] 
1245669 1284542 1 BT.84063 ENSBTAT00000002854 protein cramped-like  [Source:RefSeq peptide;Acc:NP_001192803] 
1288766 1301379 1 BT.76398 ENSBTAT00000064148 
hematological and neurological expressed 1-like 
protein  [Source:RefSeq 
peptide;Acc:NP_001075015] 
1288766 1301379 1 BT.76398 ENSBTAT00000002860 
hematological and neurological expressed 1-like 
protein  [Source:RefSeq 
peptide;Acc:NP_001075015] 
1304435 1348409 1 MAPK8IP3 ENSBTAT00000002865 C-Jun-amino-terminal kinase-interacting protein 3  [Source:RefSeq peptide;Acc:NP_001069564] 
1348415 1349600 -1 NME3 ENSBTAT00000022012 nucleoside diphosphate kinase 3 precursor  [Source:RefSeq peptide;Acc:NP_001092456] 
1349893 1351145 -1 BT.49027 ENSBTAT00000037541 28S ribosomal protein S34, mitochondrial  [Source:RefSeq peptide;Acc:NP_001030577] 
1351233 1354061 1 EME2 ENSBTAT00000022021 Uncharacterized protein  [Source:UniProtKB/TrEMBL;Acc:E1B7C9] 
1351233 1354061 1 EME2 ENSBTAT00000063538 Uncharacterized protein  [Source:UniProtKB/TrEMBL;Acc:E1B7C9] 
1351233 1354061 1 EME2 ENSBTAT00000066331 Uncharacterized protein  [Source:UniProtKB/TrEMBL;Acc:E1B7C9] 
1354553 1360122 -1 SPSB3 ENSBTAT00000022024 SPRY domain-containing SOCS box protein 3  [Source:UniProtKB/Swiss-Prot;Acc:Q3MHZ2] 
1360579 1365802 1 NUBP2 ENSBTAT00000022029 Cytosolic Fe-S cluster assembly factor NUBP2  [Source:UniProtKB/Swiss-Prot;Acc:Q3MHY6] 
1366647 1368479 -1 BT.24635 ENSBTAT00000047326 
insulin-like growth factor-binding protein complex 
acid labile subunit precursor  [Source:RefSeq 
peptide;Acc:NP_001069431] 
1379295 1391295 -1 HAGH ENSBTAT00000026635 Hydroxyacylglutathione hydrolase, mitochondrial  [Source:UniProtKB/Swiss-Prot;Acc:Q3B7M2] 
1391462 1393086 1 FAHD1 ENSBTAT00000046873 Acylpyruvase FAHD1, mitochondrial  [Source:UniProtKB/Swiss-Prot;Acc:Q2HJ98] 
1394201 1417716 -1 TPT1 ENSBTAT00000065799 Translationally-controlled tumor protein  [Source:UniProtKB/Swiss-Prot;Acc:Q5E984] 
1402494 1436118 -1 C16ORF73 ENSBTAT00000037536 Uncharacterized protein  [Source:UniProtKB/TrEMBL;Acc:E1BA02] 
1402494 1436118 -1 C16ORF73 ENSBTAT00000065143 Uncharacterized protein  [Source:UniProtKB/TrEMBL;Acc:E1BA02] 
1486479 1492437 -1 HS3ST6 ENSBTAT00000025630 Uncharacterized protein  [Source:UniProtKB/TrEMBL;Acc:E1B729] 
1508568 1515379 -1 RPL3L ENSBTAT00000012541 60S ribosomal protein L3-like  [Source:UniProtKB/Swiss-Prot;Acc:Q3SZ10] 
1517626 1520287 1 NDUFB10 ENSBTAT00000012542 
NADH dehydrogenase [ubiquinone] 1 beta 
subcomplex subunit 10  [Source:UniProtKB/Swiss-
Prot;Acc:Q02373] 
1520493 1522670 -1 RPS2 ENSBTAT00000012544 40S ribosomal protein S2  [Source:UniProtKB/Swiss-Prot;Acc:O18789] 
1520844 1520974 -1 SNORA64 ENSBTAT00000059386 Small nucleolar RNA SNORA64/SNORA10 family [Source:RFAM;Acc:RF00264] 
1521490 1521623 -1 SNORA64 ENSBTAT00000059680 Small nucleolar RNA SNORA64/SNORA10 family [Source:RFAM;Acc:RF00264] 
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1522971 1523097 1 ACA64 ENSBTAT00000062760 Small nucleolar RNA ACA64 [Source:RFAM;Acc:RF01225] 
1524318 1528358 1 RNF151 ENSBTAT00000047302 RING finger protein 151  [Source:UniProtKB/Swiss-Prot;Acc:Q2TBT8] 
1529747 1535805 1 BT.20483 ENSBTAT00000027147 transducin beta-like protein 3  [Source:RefSeq peptide;Acc:NP_001040084] 
1536097 1538058 -1 NOXO1 ENSBTAT00000047285 Uncharacterized protein  [Source:UniProtKB/TrEMBL;Acc:E1BAA4] 
1540863 1543188 1 GFER ENSBTAT00000023446 FAD-linked sulfhydryl oxidase ALR  [Source:RefSeq peptide;Acc:NP_001180117] 
1545800 1549999 1 SYNGR3 ENSBTAT00000011211 Synaptogyrin-3  [Source:UniProtKB/Swiss-Prot;Acc:A2VE58] 
1552258 1562560 -1 ZNF598 ENSBTAT00000001356 Uncharacterized protein  [Source:UniProtKB/TrEMBL;Acc:E1B928] 
1571169 1571725 1 NPW ENSBTAT00000064568 Uncharacterized protein  [Source:UniProtKB/TrEMBL;Acc:G3MWV7] 
1575649 1589619 1 BT.67331 ENSBTAT00000065244 Na(+)/H(+) exchange regulatory cofactor NHE-RF2  [Source:RefSeq peptide;Acc:NP_001070533] 
1575649 1589619 1 BT.67331 ENSBTAT00000049790 Na(+)/H(+) exchange regulatory cofactor NHE-RF2  [Source:RefSeq peptide;Acc:NP_001070533] 
1590252 1595934 -1 NTHL1 ENSBTAT00000049780 Endonuclease III-like protein 1  [Source:UniProtKB/Swiss-Prot;Acc:Q2KID2] 
1596730 1626967 1 TSC2 ENSBTAT00000049485 Uncharacterized protein  [Source:UniProtKB/TrEMBL;Acc:E1BNT2] 
1627978 1666088 -1 PKD1 ENSBTAT00000027480 Uncharacterized protein  [Source:UniProtKB/TrEMBL;Acc:E1BC86] 
1628447 1628539 -1 bta-mir-1225 ENSBTAT00000054195 bta-mir-1225 [Source:miRBase;Acc:MI0010452] 
1680110 1686192 1 RAB26 ENSBTAT00000000348 Ras-related protein Rab-26  [Source:UniProtKB/Swiss-Prot;Acc:Q29RR0] 
1693737 1693819 -1 SNORD60 ENSBTAT00000059743 Small nucleolar RNA SNORD60 [Source:RFAM;Acc:RF00271] 
1702116 1712907 1 TRAF7 ENSBTAT00000025393 E3 ubiquitin-protein ligase TRAF7  [Source:RefSeq peptide;Acc:NP_001019692] 
1714641 1725252 -1 CASKIN1 ENSBTAT00000053168 Uncharacterized protein  [Source:UniProtKB/TrEMBL;Acc:F1MB71] 
1738258 1742107 1 MLST8 ENSBTAT00000053181 Target of rapamycin complex subunit LST8  [Source:UniProtKB/Swiss-Prot;Acc:Q17QU5] 
1738258 1742107 1 MLST8 ENSBTAT00000013104 Target of rapamycin complex subunit LST8  [Source:UniProtKB/Swiss-Prot;Acc:Q17QU5] 
1742073 1743503 -1 C16ORF79 ENSBTAT00000066147 Uncharacterized protein  [Source:UniProtKB/TrEMBL;Acc:E1BH52] 
1742073 1743503 -1 C16ORF79 ENSBTAT00000013120 Uncharacterized protein  [Source:UniProtKB/TrEMBL;Acc:E1BH52] 
1744661 1744720 -1  ENSBTAT00000054214   
1744908 1744984 -1 bta-mir-2382 ENSBTAT00000062039 bta-mir-2382 [Source:miRBase;Acc:MI0011419] 
1746200 1747344 -1 PGP ENSBTAT00000013127 Phosphoglycolate phosphatase  [Source:UniProtKB/Swiss-Prot;Acc:Q2T9S4] 
1753636 1762994 1 E4F1 ENSBTAT00000013136 transcription factor E4F1  [Source:RefSeq peptide;Acc:NP_001192754] 
1763777 1766831 1 DNASE1L2 ENSBTAT00000013142 deoxyribonuclease-1-like 2 precursor  [Source:RefSeq peptide;Acc:NP_001098489] 
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Figure S2.  Identification of three private nucleotide substitutions in CLCN7 exon 23 from 
whole-genome sequencing of cases.  (A) Screen capture of an IGV output displaying the 
sequence reads from cases and controls.  (B)  Schematic representation of the bovine CLCN7 
genomic organization (adapted from UCSC browser) highlighting exon 23. 
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Figure S3.  Position-Specific Scoring Matrix (PSSM) output for the CBS2 domain of the 
mutant bovine CIC-7.  Alignment stack of the cd04591 domain (containing two tandem repeats 
of the cystathionine beta-synthase (CBS pair) domains in the EriC CLC-type chloride channels 
in eukaryotes and bacteria) for a 20 amino acid sequence around the Y750Q mutation in CBS2; a 
highly negative score (dark red) is obtained when the mutant Q750 is substituted for the wild-
type Y750 (Marchler-Bauer, A., et al. (2011). CDD: a Conserved Domain Database for the 
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Table S3.  Variations on the disease haplotype, absent from the controls.  The table displays 
the position of each unfiltered variation within the 1.15 Mb chromosomal (Chr.) region, the 
respective position (Start), the allele on bovine reference sequence (Ref.), the identified derived 
allele (Der.), the location in respect to annotated genes (Annotation), the gene encompassing the 
variation (Gene) and the amino acid substitution (Effect), if any. The three substitutions 
originally identified in CLCN7 are highlighted in orange. 
 
Chr. Start (bp) Ref. Der. Annotation Gene Effect
25 786838 G A Intergenic
25 872236 G T Intergenic
25 892640 G C Intergenic
25 902024 G C Intergenic
25 949666 G A Intergenic
25 956299 C G Intergenic
25 989738 C T Intergenic
25 1086081 C G Intronic UNKL
25 1137017 G T Coding CLCN7 Synonymous
25 1137019 A G Coding CLCN7 Y750Q
25 1137023 C G Coding CLCN7 Y750Q
25 1190837 C T Coding IFT140 R1023Q
25 1280350 C A Coding CRAMP1L Synonymous
25 1351987 G A Intronic EME2
25 1448057 G A Intergenic
25 1552885 TGGAGGCTTCCGCCTTTGG T Intronic ZNF598
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Table S4.  Primer pairs for gDNA and cDNA. 
Genomic DNA 
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Figure S4.  Western blot analysis of overexpressed ClC-7/Ostm1.  HeLa cells were 
transfected with rat ClC-7, either wild-type (WT) or mutant (MUT), and Ostm1, or with Ostm1 
alone, or mock-transfected.  Membrane protein-enriched lysates were prepared 26 hours after 
transfection and analyzed by Western blot (40 µg per lane) with antibodies against ClC-7 (7N4B, 
Kornak et al., Cell 2001) (A), or against Ostm1 (Lange et al., Nature 2006) (B).  Immunoblotting 
for α-tubulin served as loading control.  Overexpressed Ostm1 exists predominantly in its 
endoplasmic reticulum-resident, uncleaved form.  Different patterning between Ostm1 alone and 
co-expressed may be due to different glycosylation.  In the higher exposure, it is obvious that the 
processed, lysosomal form of Ostm1 is present when co-expressed with ClC-7, both wild-type 
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Figure S5.  Yearly repartition of hamartoma cases collected and concomitant carrier 
frequency evolution in the healthy Belgian Blue population.  Numbers of cases reported to 
the heredo-surveillance platform are shown in red; carrier frequency evolution, since diagnostic 
test availability (haplotype-based test from September 2009, replaced by a direct, mutation-based 
test in April 2010) until August 2013, is shown in grey; yearly number of genotyped animals is 
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